Edgewise Therapeutics, Inc.
EWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710072
In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Edgewise Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 78 | 94 | +16 |
| Shares | 51.0M | 64.4M | +13.4M (+26.3%) |
| Value | $405.7M | $633.5M | +$227.8M (+56.2%) |
New holders (22)
Institutions that held Edgewise Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (6)
Institutions that held Edgewise Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Logos Global Management LP | 150,000 | $1.19M |
| Laurion Capital Management LP | 57,213 | $455.0K |
| Ergoteles LLC | 34,600 | $275.0K |
| Acadian Asset Management LLC | 20,979 | $167.0K |
| Walleye Capital LLC | 17,000 | $135.0K |
| Captrust Financial Advisors | 263 | $2.00K |